US · LUNG
Pulmonx Corporation
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Redwood City, CA 94063
- Website
- pulmonx.com
Price · as of 2024-12-31
$1.35
Market cap 65.17M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $28.18 | +1,987.41% |
| Intrinsic Value(DCF) | $3.00 | +122.22% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $60.44 | $47.43 | $4.90 | $1.75 | $0.00 |
| 2021 | $21.75 | $34.59 | $49.62 | $0.00 | $0.00 |
| 2022 | $10.74 | $26.48 | $1.92 | $0.00 | $0.00 |
| 2023 | $9.09 | $29.10 | $2.78 | $0.00 | $0.00 |
| 2024 | $7.48 | $28.18 | $1.88 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Pulmonx Corporation's (LUNG) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $28.18
- Current price
- $1.35
- AI upside
- +1,987.41%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.00
+122.22% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LUNG | Pulmonx Corporation | $1.35 | 65.17M | +1,987% | +122% | — | — | -5.19 | 3.41 | 3.49 | -4.87 | — | 3.50 | 74.00% | -68.87% | -67.30% | -55.25% | -138.32% | -33.11% | 0.66 | -16.45 | 5.58 | 4.72 | 0.28 | -1000.00% | 2201.00% | -1414.00% | -11.27% | -1.29 | -79.07% | 0.00% | 0.00% | 0.00% | -4.29 | -7.50 | 2.95 | -1.57 |
| ACRV | Acrivon Therapeutics, Inc… | $1.51 | 47.65M | — | — | — | — | -2.63 | 1.20 | — | -0.46 | — | 1.20 | 0.00% | — | — | -54.07% | 26706.29% | -48.11% | 0.02 | — | 10.55 | 10.43 | 0.45 | -2336.00% | — | 5579.00% | -32.26% | -3.81 | 20490.12% | 0.00% | 0.00% | 2.26% | -0.41 | -0.53 | — | 4.53 |
| ASRT | Assertio Holdings, Inc. | $11.66 | 74.82M | +1,017% | +6,046% | -82% | +159% | -3.44 | 0.61 | 0.59 | 2.82 | — | 1.83 | 68.61% | -19.59% | -17.27% | -16.66% | -29.57% | -7.56% | 0.33 | -8.05 | 1.77 | 1.34 | -2.01 | -9507.00% | -1783.00% | -4608.00% | 35.54% | 0.23 | 31.91% | 0.00% | 0.00% | 0.47% | -0.59 | 0.55 | 0.12 | -2.51 |
| EDAP | Edap Tms S.a. | $4.37 | 163.4M | +598% | -76% | — | — | -4.26 | 1.98 | 1.26 | -4.08 | — | 2.16 | 41.42% | -32.03% | -29.66% | -38.88% | -87.65% | -21.42% | 0.34 | -87.01 | 1.85 | 1.33 | 1.00 | -1053.00% | 611.00% | -679.00% | -21.85% | -0.36 | -75.49% | 0.00% | 0.00% | 0.00% | -3.17 | -3.68 | 1.01 | 0.14 |
| HYPR | Hyperfine, Inc. | $1.07 | 81.53M | +2,340% | -64% | — | — | -1.74 | 1.45 | 5.51 | -0.80 | — | 1.45 | 45.70% | -335.33% | -315.90% | -61.03% | -410.39% | -53.19% | 0.01 | — | 6.15 | 5.26 | 0.89 | -968.00% | 1684.00% | -813.00% | -55.17% | -4.44 | -371.71% | 0.00% | 0.00% | 0.00% | -0.78 | -0.86 | 2.61 | -3.97 |
| IMUX | Immunic, Inc. | $1.02 | 100.66M | — | — | — | — | -16.98 | -247.31 | — | -16.85 | — | -247.31 | 0.00% | — | — | -1653.15% | 539.27% | -299.36% | -0.02 | — | 0.75 | 0.64 | 0.16 | -3800.00% | — | 110.00% | -5.21% | -2.80 | 449.10% | 0.00% | 0.00% | 0.00% | -15.84 | -19.02 | — | -17.75 |
| PMVP | PMV Pharmaceuticals, Inc. | $1.70 | 90.46M | — | — | — | — | -1.08 | 0.36 | — | 1.42 | — | 0.36 | 0.00% | — | — | -29.23% | -306.66% | -26.48% | 0.01 | — | 12.22 | 11.79 | 0.54 | -2096.00% | — | -827.00% | -81.87% | -3.57 | -237.51% | 0.00% | 0.00% | 24.06% | 1.23 | 2.02 | — | -0.66 |
| RLMD | Relmada Therapeutics, Inc… | $4.56 | 334.4M | — | — | — | — | -0.11 | 0.24 | — | 0.43 | — | 0.24 | 0.00% | — | — | -132.33% | 824.32% | -111.57% | 0.00 | — | 4.45 | 4.36 | 0.05 | -1921.00% | — | 19.00% | -597.84% | -5.03 | 508.56% | 0.00% | 0.00% | 0.00% | 0.43 | 0.70 | — | -24.19 |
| TCRX | TScan Therapeutics, Inc. | $1.06 | 60.15M | +2,649% | +18% | — | +7,924% | -1.74 | 0.92 | 78.74 | -0.24 | — | 0.92 | 100.00% | -4787.68% | -4527.66% | -65.08% | -271.01% | -39.64% | 0.40 | -36.91 | 8.14 | 8.07 | 0.68 | -1618.00% | -8662.00% | 7774.00% | -51.70% | -3.08 | -230.45% | 0.00% | 0.00% | 18.21% | -0.22 | -0.25 | 10.30 | -0.75 |
| TELA | TELA Bio, Inc. | $0.87 | 38.66M | +2,769% | +12% | — | — | -1.82 | 2.43 | 1.00 | -1.88 | — | 2.58 | 67.08% | -49.23% | -54.60% | -159.87% | -201.31% | -45.76% | 1.51 | -6.45 | 5.01 | 4.02 | 0.30 | -3480.00% | 1856.00% | 269.00% | -61.69% | -2.67 | -252.24% | 0.00% | 0.00% | 8.18% | -1.74 | -1.40 | 0.86 | -4.68 |
About Pulmonx Corporation
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
- CEO
- Glendon E. French
- Employees
- 291
- Beta
- 0.07
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.00 ÷ $1.35) − 1 = +122.22% (DCF, example).